Six months' chemotherapy for lymph node tuberculosis

McCarthy, O.R.; Rudd, Robin

doi:10.1016/s0954-6111(89)80075-7

Cited by 20 publications

(16 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Medication taken for less than 30 days did not count towards treatment. Standard treatment for TBL consisted of at least three first-line drugs for the initial two months of a minimum six month duration of therapy as outlined by treatment guidelines (14)(15)(16)(17). Nonstandard treatment included use of second-line drugs (ciprofloxacin, ethionamide, rifabutin, capreomycin and clofazimine), less than three drugs, or the duration of treatment of less than six months.…”

Section: Case Characteristics and Treatmentmentioning

confidence: 99%

Tuberculous Lymphadenitis in Manitoba: Incidence, Clinical Characteristics and Treatment

Cook¹,

Manfreda²,

Hershfield³

2004

Canadian Respiratory Journal

View full text Add to dashboard Cite

BACKGROUND:Tuberculous lymphadenitis (TBL) is an important form of extrapulmonary tuberculosis (TB). Recent studies have shown an increase in TBL in Canada.OBJECTIVES:To determine the incidence of TBL in Manitoba and to identify the characteristics associated with its presentation, diagnosis and treatment.METHODS:Population data from the Manitoba Health Population Registry, the First Nations and Inuit Health Branch of Health Canada, and Statistics Canada were used to calculate incidence. Case characteristics and outcomes were determined by a systematic, retrospective review of all cases between January 1, 1990 and December 31, 2000.RESULTS:One-hundred forty seven cases of TBL were identified during the study period; 77% confirmed by culture; 68% women. TBL was found in Canadian-born/nonstatus Aboriginal (12%), status Aboriginal (29%) and foreign-born (59%) populations. Incidence of TBL was 1.17 per 100,000 person years (95% CI 0.98 to 1.36). The highest incidence was in status Aboriginals over 65 years (16.85 per 100,000 person years; 95% CI 3.37 to 30.33). TBL is seen most often in Western Pacific women. The most common presentation was a single, enlarged cervical node (80%). No atypical mycobacterium was found. Drug resistance occurred in 13% of cases and only in the foreign-born. Cure rates (81%) were influenced by comorbidity and burden of TB disease. Relapse occurred in 8.1 per 1000 person years of follow-up (95% CI 1.7 to 23.7).CONCLUSIONS:Respiratory physicians, who manage the majority of TB disease in Canada, need to remain aware that TB is an important and treatable cause of enlarged lymph nodes.

show abstract

Section: Case Characteristics and Treatmentmentioning

confidence: 99%

Tuberculous Lymphadenitis in Manitoba: Incidence, Clinical Characteristics and Treatment

Cook¹,

Manfreda²,

Hershfield³

2004

Canadian Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…During treatment, new nodes or enlargement of existing lymph nodes occurred in 79/468=17% [7,8,10,11,13]. Nodes were present after treatment in 143/423=34% of the patients [7,8,10,11,13].…”

Section: Resultsmentioning

confidence: 99%

“…Nodes were present after treatment in 143/423=34% of the patients [7,8,10,11,13]. The size of the nodes was not reported, or the nodes were not suspected of harbouring disease.…”

Section: Resultsmentioning

confidence: 99%

“…In one of these patients, the residual lymph node resolved spontaneously within 3 months and another patient with a residual node of 1 cm at the end of treatment was lost to follow-up [13]. 2HRZ(E)/7HR*** 9 0 93*** 100*** 12-0/9…”

Section: Resultsmentioning

confidence: 99%

“…In three out of these 16 patients, the relapse was bacteriologically confirmed, while in four it was histologically proven [7,8]. Five patients relapsed during the first year [7,8,13] three patients relapsed later, and in eight patients there was no further information [7±12].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Cervical tuberculous lymphadenitis

Eyselbergs¹,

Snoeckx²,

Beeck³

et al. 2011

Journal of the Belgian Society of Radiology

View full text Add to dashboard Cite

The aim of the study was to determine the optimal duration of treatment for patients with tuberculous lymphadenitis.The Medline database was searched for relevant articles published between 1978± 1997. Inclusion criteria were study populations of patients with predominantly cervical tuberculous lymphadenitis in whom the diagnosis had been confirmed bacteriologically and/or histologically, or was made probable by using clinical and laboratory markers. Treatment management had to include at least isoniazid, rifampicin and pyrazinamide and a follow-up of at least 12 months after the end of treatment. Patients with resistance to rifampicin and pyrazinamide and previous treatment for tuberculosis were excluded. The number of patients who relapsed after treatment was calculated.The study population in eight out of the 35 articles retrieved were suitable for analysis. Some concerned comparative studies. There were eight treatment schedules of 6 months' duration and three schedules of 9 months' duration. Treatment for 6 months resulted in a tuberculous lymphadenitis relapse rate of 13/422=3.3% (95% confidence interval: 1.7±5.5), with a mean follow-up of 31 months after completion of treatment. Treatment for 9 months resulted in a relapse rate of 3/112=2.7% (95% confidence interval: 0.6±7.8), with a mean follow-up of 20 months.Despite the limitations of the literature available, 6 months of therapy is probably sufficient for patients with tuberculous lymphadenitis.

show abstract

Tuberculous Lymphadenitis

Powell¹

1994

Tuberculosis

View full text Add to dashboard Cite

Six months' chemotherapy for lymph node tuberculosis

Cited by 20 publications

References 3 publications

Tuberculous Lymphadenitis in Manitoba: Incidence, Clinical Characteristics and Treatment

Tuberculous Lymphadenitis in Manitoba: Incidence, Clinical Characteristics and Treatment

Cervical tuberculous lymphadenitis

Tuberculous Lymphadenitis

Contact Info

Product

Resources

About